心肌梗死患者溶栓治疗疗效与D-二聚体水平的关系

目的评价血浆D-二聚体（DD）在判断急性心肌梗死（AMI）溶栓治疗疗效中的应用价值。方法采用酶联免疫吸附试验（ELISA）检测健康人（对照组）心绞痛、陈旧性心肌梗死（OMI）及AMI患者血浆DD含量（AMI患者发病后进行连续测定），并比较其结果。结果对照组、心绞痛患者、OMI患者、未接受溶栓的AMI患者、接受溶栓治疗的AMI患者DD含量分别为0．41±0．30mg／L、0．55±0．36mg／L、0．60±0．48mg／L、1．01±0．52mg／L和2．91±1．04mg／L。与对照组相比较，心绞痛组和OMI组DD含量差异无显著性（P〉0．05），而未溶AMI组和溶栓AMI组DD含量明显升高，差异具有非常显著性（P〈0．001）。溶栓AMI组DD含量显著高于未溶AMI组，差异具有显著性（P〈0．001）。结论血浆DD测定不仅可作为观察心肌梗死病情的指标，对溶栓药物的疗效监测也具有重要价值。

Myocardial infarction in patients with thrombolytic therapy efficacy and D-dimer levels

Objective Evaluation of plasma D - dimer （ D - dimer, DD） in the diagnosis of acute myocardial infarction （AMI） thrombolytic treatment of the clinical value. Methods By ELISA test angina, old myocardial infarction （OMI） and acute myocardial infarction （AMI） in patients with DD （ AMI after the onset of a row） , and compare the results. Results The control group, patients with angina pectoris, patients with angina pectoris, patients with OMI, AMI patients without receiving thrembolytic, patients receiving thrombolytic therapy for patients with AMI the content of DD in plasma were respectively 0.41 ± 0.30 mg/L, 0.55 ± 0, 36 mg/L, 0.60 ± 0.48 mg/L, 1.02 ± 0.50 mg/L, 2.91 ± 1.04 mg/L. In comparison to the contrast group, patients with angina pectoris and patients with OMI, the content of DD in plasma was no significant difference among them, but have significant difference among AMI patients without receiving thrombolytic and patients receiving thrombolytic therapy. Patients receiving thrombolytie therapy was significantly higher than that in patients without receiving thrombnlytic group, there were significant differences between them. Conclusion Determination of plasma DD not only can be used as observation of myocardial infarction condition indicators, the efficacy of thrombolytic drug monitoring is also of major value.